• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile?

    Simply Wall St·09/07/2026 05:23:41
    語音播報
    • In August 2026, Biohaven Ltd. announced a global licensing and collaboration agreement granting SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), with Biohaven set to receive up to US$795 million in upfront and milestone payments plus tiered royalties on U.S. net sales.
    • The deal not only brings Biohaven US$400 million in near-term cash and up to US$150 million in additional milestones, but also shifts substantial future Kv7 development and milestone obligations, including up to US$245 million in program costs, to SK Biopharmaceuticals, reshaping Biohaven’s risk and funding profile.
    • Next, we’ll examine how offloading future Kv7 development costs to SK Biopharmaceuticals influences Biohaven’s investment narrative and capital allocation flexibility.

    The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    What Is Biohaven's Investment Narrative?

    To own Biohaven today, you really have to believe its early science can eventually justify heavy, ongoing losses, despite zero revenue and a very large negative return on equity. The SK Biopharmaceuticals deal matters here: shifting up to US$245 million of future Kv7 costs off Biohaven’s books and bringing in US$400 million of near-term cash should ease the previous concern about a short cash runway and soften the near-term need for fresh equity. At the same time, it moves one of Biohaven’s nearer-term epilepsy catalysts partly outside the company, refocusing attention on its degraders (BHV-1300, BHV-1400) and other pipeline assets as the key value drivers. Given the volatile share price, persistent losses and shareholder dilution, the risk side of the story still feels very real.

    However, shorter cash runway concerns may not be fully resolved by this deal. Biohaven's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

    Exploring Other Perspectives

    BHVN 1-Year Stock Price Chart
    BHVN 1-Year Stock Price Chart
    Two Simply Wall St Community fair values, from about US$21.73 to US$71.76, show how far apart retail views can be. Set that next to Biohaven’s ongoing losses and pipeline dependency, and it is easy to see why investors may want to weigh several contrasting scenarios before deciding how this company might fit into a portfolio.

    Explore 2 other fair value estimates on Biohaven - why the stock might be worth just $21.73!

    Decide For Yourself

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Biohaven?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.